Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:7010-7011.

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

Jingyu Zhu _, Man Wang, Yang Yu, Huixin Qi, Kunkun Han, Juan Tang, Zubin Zhang, Yuanying Zeng, Biyin Cao, Chunhua Qiao, Hongjian Zhang, Tingjun Hou and Xinliang Mao

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:185-195. https://doi.org/10.18632/oncotarget.2688

Metrics: PDF 2147 views  |   HTML 2161 views  |   ?  


Abstract

Jingyu Zhu1,2,*, Man Wang1,2,*, Yang Yu3, Huixin Qi4, Kunkun Han1,2, Juan Tang1,2, Zubin Zhang1,2, Yuanying Zeng1,2, Biyin Cao1,2, Chunhua Qiao3, Hongjian Zhang4, Tingjun Hou1,5, Xinliang Mao1,2

1Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-psycho-diseases, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

2Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China

3Department of Medicinal Chemistry, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

4Department of Pharmaceutical Analysis, College of Pharmaceutical Sciences, Soochow University, Suzhou, China

5Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

*These two authors equally contributed to this study

Correspondence to:

Xinliang Mao, e-mail: Xinliangmao@suda.edu.cn
Tingjun Hou, e-mail: tingjunhou@zju.edu.cn

Keywords: phosphatidylinositol-3-kinase, multiple myeloma, C98, virtual screen

Received: August 14, 2014     Accepted: November 02, 2014     Published: December 02, 2014

ABSTRACT

Recent clinical trials have demonstrated targeting PI3K pathway is a promising strategy for the treatment of blood cancers. To identify novel PI3K inhibitors, we performed a high throughput virtual screen and identified several novel small molecule compounds, including PIK-C98 (C98). The cell-free enzymatic studies showed that C98 inhibited all class I PI3Ks at nano- or low micromolar concentrations but had no effects on AKT or mTOR activity. Molecular docking analysis revealed that C98 interfered with the ATP-binding pockets of PI3Ks by forming H-bonds and arene-H interactions with specific amino acid residues. The cellular assays demonstrated that C98 specifically inhibited PI3K/AKT/mTOR signaling pathway, but had no effects on other kinases and proteins including IGF-1R, ERK, p38, c-Src, PTEN, and STAT3. Inhibition of PI3K by C98 led to myeloma cell apoptosis. Furthermore, oral administration of C98 delayed tumor growth in two independent human myeloma xenograft models in nude mice but did not show overt toxicity. Pharmacokinetic analyses showed that C98 was well penetrated into myeloma tumors. Therefore, through a high throughput virtual screen we identified a novel PI3K inhibitor that is orally active against multiple myeloma with great potential for further development.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2688